Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINTEPLA vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older,Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Fenfluramine is primarily metabolized by CYP1A2, CYP2B6, and CYP2D6 to its active metabolite norfenfluramine. Norfenfluramine is further metabolized by CYP2D6 and other enzymes.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Approximately 55% bound to plasma proteins, primarily albumin.
16% (primarily albumin).
Apparent volume of distribution (Vd/F) approximately 2.5–3.5 L/kg, suggesting extensive extravascular distribution.
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral bioavailability approximately 80% (relatively high first-pass metabolism: moderate).
Oral IR: ~90%; ER: ~90%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
Mild hepatic impairment (Child-Pugh A): maximum dose 11 mg/day. Moderate to severe (Child-Pugh B or C): not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
For patients weighing 10-50 kg: initial 0.05 mg/kg twice daily; titrated to 0.1 mg/kg twice daily (target), may increase to 0.2 mg/kg twice daily (max). For patients weighing ≥50 kg: same as adult dosing (max 16 mg/day). Not established for weight <10 kg.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
No specific dose adjustment; start at low end of dosing range due to greater frequency of decreased hepatic/renal function and concomitant disease.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
Valvular heart disease and pulmonary arterial hypertension: FINTEPLA is associated with valvular heart disease (e.g., mitral and aortic regurgitation) and pulmonary arterial hypertension. Patients must undergo echocardiography before starting treatment, at 3 months, and every 6-12 months thereafter.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Valvular heart disease and pulmonary arterial hypertension: monitor with echocardiography,Increased intraocular pressure: caution in patients with glaucoma,Suicidal thoughts and behavior: monitor for worsening depression and suicidality,Dizziness, somnolence, and fatigue: may impair ability to drive or operate machinery,Decreased appetite and weight loss: monitor weight, especially in pediatric patients,Potential for abuse and dependence: controlled substance (Schedule IV)
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation of an MAOI,Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) due to risk of serotonin syndrome,Hypersensitivity to fenfluramine or any component of the formulation
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
Avoid grapefruit and grapefruit juice as they are CYP1A2 inhibitors and may increase fenfluramine exposure. No other significant food interactions reported.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In animal studies, fenfluramine caused embryofetal mortality and structural abnormalities at clinically relevant doses. During the second and third trimesters, exposure may lead to fetal growth restriction and neurodevelopmental effects. Use during pregnancy is contraindicated unless no safer alternative exists.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Fenfluramine is excreted into human breast milk; the milk-to-plasma (M/P) ratio is approximately 0.5. Based on limited data, the relative infant dose is estimated to be <10% of the maternal weight-adjusted dose. However, prolonged exposure may cause adverse effects in the infant (e.g., irritability, feeding difficulties). Breastfeeding is not recommended during FINTEPLA therapy due to potential for serious adverse reactions.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic studies. However, physiological changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may necessitate therapeutic drug monitoring and dose titration. Use lowest effective dose and consider alternative agents if possible.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
FINTEPLA (fenfluramine) is indicated for seizures associated with Dravet syndrome. Monitor for valvular heart disease and pulmonary arterial hypertension due to serotonergic effects; obtain baseline and periodic echocardiograms. Titrate slowly to minimize appetite suppression and weight loss. Avoid concurrent use with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs due to risk of serotonin syndrome. Dose adjustment required in hepatic impairment.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take exactly as prescribed; do not stop abruptly as withdrawal may increase seizure frequency.,Common side effects include decreased appetite, weight loss, diarrhea, and fatigue.,Report any signs of heart problems such as shortness of breath, chest pain, or swelling of ankles.,Avoid grapefruit and grapefruit juice during treatment as it may increase drug levels.,Women of childbearing potential should use effective contraception due to potential fetal harm.,Do not drive or operate heavy machinery until you know how the medication affects you.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINTEPLA vs ADDERALL 20, answered by our medical review team.
FINTEPLA is a Antiepileptic that works by Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINTEPLA and ADDERALL 20 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINTEPLA is: 0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINTEPLA and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINTEPLA is classified as Category C. FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In ani. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.